No abstract

The clinical profile of reboxetine, a selective noradrenaline reuptake inhibitor, was compared with that of the selective serotonin reuptake inhibitor fluoxetine and placebo in a double-blind, multicenter, parallel-group clinical trial of patients with major depression. Among the 381 patients treated with reboxetine 8 to 10 mg/day, fluoxetine 20 to 40 mg/day, or placebo for up to 8 weeks, a statistically significant greater reduction in the mean Hamilton Rating Scale for Depression (21-item HAM-D) total score (the primary efficacy variable) was seen for both active treatment groups compared with placebo (p < 0.024). A significantly greater proportion of patients treated with either reboxetine or fluoxetine also achieved a response (>or=50% reduction in HAM-D) or remission (HAM-D

SUMMARY Five patients with multiple sclerosis and four normal subjects have been followed for over two years. Plasma phospholipid levels and phospholipid fatty acid composition have been assayed periodically. The increased amount of plasma lysolecithin already described by us has been confirmed in this longitudinal study. A significant increase in saturated fatty acids of lysolecithin has also been demonstrated. In contrast, the lecithin concentration and fatty acid composition do not show any significant variations. The lysolecithin saturated/unsaturated fatty acid ratio was different in the same patients at different times, but no correlation was established between these variations and the clinical symptoms measured using the Kurtzke scale. The possible significance of saturated fatty acid increase in lysolecithin in the pathogenetic mechanisms of multiple sclerosis is discussed.

No abstract

No abstract